Cancer clinical trials in the region Pays de la Loire
440 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 2 / Phase 3
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Pancreas cancer
Stomach and esophageal cancer
Cervical / Vulvar / Vaginal cancer
Small intestine and appendix cancer
#NCT06943755
#2025-521043-20-00
Required histologic sub types
Neuroendocrine tumor
Required disease stage
Locally Advanced
Metastatic
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
11 recruiting sites
Exélixis
Phase 2 / Phase 3
Stomach and esophageal cancer
#NCT07221149
#2025-523263-37-00
Required histologic types
Stomach
Oesogastric junction
Esophagus
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Negative (< 1)
CPS Positive (1 <= X < 5)
CPS Positive (5 <= X < 10)
CPS Positive (X >= 10)
Excluded genetic anomalies
HER2
5 recruiting sites
Bristol-Myers Squibb
Phase 2 / Phase 3
Lung cancer
#NCT07100080
#2025-521908-22-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Targeted therapy
1 recruiting site
Bristol-Myers Squibb
Phase 2 / Phase 3
Bladder / Urinary Tract / Urethral cancer
#NCT07106762
#2025-522400-24-00
Required histologic types
Invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Chemotherapy
Antibody Drug Conjugates (ADC)
10 recruiting sites
Bristol-Myers Squibb
Phase 2 / Phase 3
Lung cancer
#NCT05255302
#2024-515945-40-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC
Non-squamous NSCLC
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
EGFR
HER2
NTRK-1/2/3
RET
ROS-1
Other mutation
Excluded previous treatments at localized stage
Immunotherapy
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Targeted therapy
12 recruiting sites
Intergroupe Francophone de Cancérologie Thoracique
Phase 2
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT06517875
#2024-518225-15-00
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis
Secondary myelofibrosis
Required number of previous lines of therapy
None
1
2
3 or more
Required DIPSS scores
Intermediate-1
Intermediate-2
High
7 recruiting sites
GlaxoSmithKline
Phase 2
Acute leukemia
#NCT07522801
#2024-516570-30-00
Required histologic types
Acute lymphoblastic leukemia (ALL)
Required histologic sub types
T-cell (T-ALL)
Required central nervous system lesions
None
Treated / Controled
Required number of previous lines of therapy
1
2
Excluded previous treatments
Systemic Treatment-Naive
49 recruiting sites
Hôpital de Versailles
Phase 2
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT04419649
#2023-507469-24-00
Partie 2 Cohorte G
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
MDS de novo
Required number of previous lines of therapy
1
Required previous treatments
Erythroid maturation agent
Required medullary blasts
< 5 %
Required IPSS-R prognostic scores
Very low
Low
Intermediate
Excluded genetic anomalies
del(5q)
5 recruiting sites
Takeda
Phase 2
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT04419649
#2023-507469-24-00
Partie 2 Cohorte D
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
Chronic myelomonocytic leukemia (CMML)
Required number of previous lines of therapy
None
Required medullary blasts
< 5 %
Excluded genetic anomalies
del(5q)
5 recruiting sites
Takeda
Phase 2
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT04419649
#2023-507469-24-00
Partie 1 Escalade de dose
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
MDS de novo
Required number of previous lines of therapy
None
1
Required previous treatments
Systemic Treatment-Naive
EPO / Growth factors
Required medullary blasts
< 5 %
Required IPSS-R prognostic scores
Very low
Low
Intermediate
Excluded genetic anomalies
del(5q)
Excluded previous treatments
Chemotherapy
Erythroid maturation agent
Immunomodulator
5 recruiting sites
Takeda